OUR PEOPLE

Dani Offen, Ph.D.

Principle Investigator

danioffen@gmail.com

Tali Ben-Zur, Ph.D.

Lab Manager

tali_ben_zur@yahoo.com 
 

Shay Herman

Ph.D. Student

The Role of Exosomes in the Progression and Pathology of  Parkinson’s Diseases

Recent in-vitro and in-vivo studies support the idea of transcellular spread of misfolded alpha-synuclein in a prion-like transmission of protein aggregation.  It has been established that pathogenic alpha-synuclein can pass from cell to cell via exosome secretion. To better understand the implications of alpha-synuclein propagation via exosomes we would like to inhibit exosome synthesis by chemical and genetic methods such as CRISPR/Cas9 system to reduce alpha-synuclein spread as a therapeutic target and halt the progression of the disease.

herman.shay@gmail.com

67830129_10157725983315087_4710398651950
Woman with White Shirt

Reut Guy

Ph.D. Student

Effects of Modified Mesenchymal Stem Cell-Derived Exosomes in Murine Models of Stroke

Stroke is the second most common cause of death, and the third most common cause of disability worldwide.Research shows MSC-derived exosomes retain some of the characteristics of their parent MSCs, such as immune system modulation, regulation of neurite outgrowth, promotion of angiogenesis, and the ability to repair damaged tissue. In my research a modified MSC-derived exosomes system will be established, in which different molecular agents will be encapsulated into exosomes. Protective effects and therapeutic potential of the modified MSC-derived exosomes will be assessed both in vitro and in various murine models of stroke in vivo

rg.reutguy@gmail.com

Roy Rabinowitz

Ph.D. Student

Allele-specific correction of disease causing mutations:  The CRISPR/Cas system can be employed to specifically target a pathogenic allele and generate an allele-specific double-stranded break. In heterozygous patients such breaks may be corrected by gene conversion as the homologous chromosome serves as the correction template. Otherwise the break will lead to knockout of the pathogenic allele via NHEJ repair pathway. To increase the specificity of the CRISPR system to a single nucleotide we design the gRNAs according to the SNP-derived PAM approach.
Bioinformatic tools for gRNA design: The tools CrisPam and BE-FF were developed from the need of experimentalist researchers to treat specific single-nucleotide variations (SNVs). CrisPam identifies novel PAMs generated by SNVs to design allele-specific alleles. BE-FF (Base editors Functional Finder) identifies base editors that can precisely correct SNVs. Both tools are available as online web tools and were used to generate databases of human pathogenic SNPs that can be edited by SNP-derived PAM or base editing. 

rabinowitz.roy@gmail.com

WhatsApp Image 2021-06-26 at 21.04.08.jp

Danit Lesovoy

M.Sc. Student

danitlesovoy@mail.tau.ac.il

haleli_edited.jpg

Haleli Shen

Ph.D Student

leloosh@gmail.com

Alumni Lab Members

Reut Horev

M.Sc.

Therapeutic effect and mechanism of mesenchymal stem cells-derived exosomes in genetically modified autism model mice Shank3.

Rotem Volkman

Ph.D.

Targeting Myeloperoxidase-mediated Neutrophil Response as a Therapeutic target for Neurodegenerative Diseases

 

Shani Poleg

 M.D-Ph.D. 

Enhancement of cannabinoid signaling in mouse models of neuro-psychiatric disorders

Hadas Tsivion

M.D-Ph.D. 

The role of glutamatergic dysfunction in schizophrenia models

Ariel Angel

Ph.D. 

Caspase-6 knock-out using CRISPR/Cas9 improves cognitive behavior in the 3xTg mouse model of Alzheimer’s disease

Nisim Perets

Ph.D. 

The Big Potential of the Small Nanovesicles

Ariane Anidjar

M.Sc. 

Calpain KO using the CRISPR- CAS9 as a potential treatment for Alzheimer Disease (AD)

Shmuel Berenstein

M.Sc. 

In-vivo reprogramming towards dopaminergic fate

Alex Burshtein

M.Sc.

Adi Shruster

Ph.D.

Chen Benkler

Ph.D.

Development of nover gene therapy approach for neuroprotection in models of amyotrophic lateral sclerosis.

CV

Thesis

cbenkler@fas.harvard.edu

Lior Molcho

M.Sc.

New therapeutic approaches to promote functional outcome and recovery in mouse model of focal ischemic injury

Thesis

lior_molcho@hotmail.com

Hadar Segal-Gavish

MD-Ph.D.

Israel Aharony

MD-Ph.D.

Mutant Huntingtin proteolysis regulation as a potential treatment for Huntington's disease.

CV

Thesis

elik.aharony@gmail.com

Inna Kan

Ph.D.

Hanoch Elkon

Ph.D.

 

Javier Ganz

Ph.D.

Oral Mucosa stem cells for cell therapy of neurological disorders.

CV

Thesis

javierganz@gmail.com

Merav Bahat-Stroomza

Ph.D.

 

Mica Glat

Ph.D.

Development of genetic and pharmacological approaches for enhancing neuroprotection and nerve regeneration.

CV

Thesis

micaglat@gmail.com

Michal Dadon-Nachum

Ph.D.

Netta Shraga (Blondheim)

M.Sc.

Potential Use of Bone Marrow Derived Mesenchymal Stem Cells for Treatment of Multiple Sclerosis

CV

Thesis Abstract

 

Ofer Sadan

MD-Ph.D.

Neurotrophic factors-secreting Mesenchymal stem cells for the therapy of neurodegenerative disease models

CV

Thesis

ofer.sadan@gmail.com

Omri Lamm

M.Sc.

Nirit Lev

MD-Ph.D.

 

Ran Barzilay

MD-Ph.D.

Induction of dopaminergic differentiation on human bone marrow stem cells as possible cellular therapy for Parkinson's disease.

CV

Thesis

barzilyr@gmail.com

Yonit Fisher-Shoval

Ph.D.

 

Sharon Gai-Castro

M.Sc.​

 

Yossef Levy

Ph.D.

Induction of human bone-marrow derived Mesenchymal stem cells differentiation towards dopaminergic fates.

CV

Thesis

YLevy@brainstorm-cell.com

Yossi Gilgun-Sherki

Ph.D.